You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
|
|---|---|
| Published in |
BMC Cancer, November 2019
|
| DOI | 10.1186/s12885-019-6273-1 |
| Pubmed ID | |
| Authors |
Hannah L. Buckley, Fiona J. Collinson, Gemma Ainsworth, Heather Poad, Louise Flanagan, Eszter Katona, Helen C. Howard, Geraldine Murden, Rosamonde E. Banks, Joanne Brown, Galina Velikova, Tom Waddell, Kate Fife, Paul D. Nathan, James Larkin, Thomas Powles, Sarah R. Brown, Naveen S. Vasudev |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 91 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 11 | 12% |
| Student > Master | 10 | 11% |
| Researcher | 8 | 9% |
| Student > Doctoral Student | 7 | 8% |
| Student > Bachelor | 7 | 8% |
| Other | 21 | 23% |
| Unknown | 27 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 27% |
| Nursing and Health Professions | 12 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Unspecified | 5 | 5% |
| Biochemistry, Genetics and Molecular Biology | 4 | 4% |
| Other | 13 | 14% |
| Unknown | 27 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 November 2019.
All research outputs
#13,973,916
of 23,177,498 outputs
Outputs from BMC Cancer
#3,195
of 8,405 outputs
Outputs of similar age
#186,710
of 360,037 outputs
Outputs of similar age from BMC Cancer
#57
of 176 outputs
Altmetric has tracked 23,177,498 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,405 research outputs from this source. They receive a mean Attention Score of 4.4. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 360,037 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 176 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.